PI3K / Akt Signaling
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1060S | 100 μg | 16,000 | |
|
FoxO1/3a抗体製品一覧
| 使用目的 | |
| Phospho-FoxO1 (Thr24)/FoxO3a (Thr32) Antibody （#9464）の反応をブロックし、抗体の反応特異性を確認するために使用 |
Western Blotting
Western blot analysis of extracts from HeLa cells serum-starved for 48 hours or serum-treated for 30 minutes, using Phospho-Fox01 (Thr24)/Fox03a (Thr32) Antibody #9464 (left) or the same antibody preincubated with Phospho-Fox01 (Thr24)/Fox03a (Thr32) Blocking Peptide.
The Forkhead family of transcription factors is involved in tumorigenesis of rhabdomyosarcoma and acute leukemias (1-3). Within the family, three members (FoxO1, FoxO4, and FoxO3a) have sequence similarity to the nematode orthologue DAF-16, which mediates signaling via a pathway involving IGFR1, PI3K, and Akt (4-6). Active forkhead members act as tumor suppressors by promoting cell cycle arrest and apoptosis. Increased expression of any FoxO member results in the activation of the cell cycle inhibitor p27 Kip1. Forkhead transcription factors also play a part in TGF-β-mediated upregulation of p21 Cip1, a process negatively regulated through PI3K (7). Increased proliferation results when forkhead transcription factors are inactivated through phosphorylation by Akt at Thr24, Ser256, and Ser319, which results in nuclear export and inhibition of transcription factor activity (8). Forkhead transcription factors can also be inhibited by the deacetylase sirtuin (SirT1) (9).
-
Anderson, M.J. et al. (1998) Genomics 47, 187-199.
-
Galili, N. et al. (1993) Nat. Genet. 5, 230-235.
-
Borkhardt, A. et al. (1997) Oncogene 14, 195-202.
-
Nakae, J. et al. (1999) J. Biol. Chem. 274, 15982-15985.
-
Rena, G. et al. (1999) J. Biol. Chem. 274, 17179-17183.
-
Guo, S. et al. (1999) J. Biol. Chem. 274, 17184-17192.
-
Seoane, J. et al. (2004) Cell 117, 211-223.
-
Arden, K.C. (2004) Mol. Cell 14, 416-418.
-
Yang, Y. et al. (2005) EMBO J. 24, 1021-1032.
